- Home
- MESO vs ESRT Comparison
MESO vs ESRT Comparison
Compare MESO & ESRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- ESRT
- Stock Information
- Founded
- MESO 2004
- ESRT 2011
- Country
- MESO Australia
- ESRT United States
- Employees
- MESO N/A
- ESRT N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- ESRT Real Estate Investment Trusts
- Sector
- MESO Health Care
- ESRT Real Estate
- Exchange
- MESO Nasdaq
- ESRT Nasdaq
- Market Cap
- MESO 1.3B
- ESRT 1.2B
- IPO Year
- MESO N/A
- ESRT 2013
- Fundamental
- Price
- MESO $15.17
- ESRT $7.15
- Analyst Decision
- MESO Buy
- ESRT Hold
- Analyst Count
- MESO 4
- ESRT 2
- Target Price
- MESO $18.00
- ESRT $10.65
- AVG Volume (30 Days)
- MESO 314.4K
- ESRT 1.9M
- Earning Date
- MESO 08-28-2025
- ESRT 07-23-2025
- Dividend Yield
- MESO N/A
- ESRT 1.96%
- EPS Growth
- MESO N/A
- ESRT N/A
- EPS
- MESO N/A
- ESRT 0.23
- Revenue
- MESO $5,670,000.00
- ESRT $763,282,000.00
- Revenue This Year
- MESO $177.23
- ESRT $3.48
- Revenue Next Year
- MESO $314.04
- ESRT $2.79
- P/E Ratio
- MESO N/A
- ESRT $30.67
- Revenue Growth
- MESO N/A
- ESRT 1.08
- 52 Week Low
- MESO $5.78
- ESRT $6.56
- 52 Week High
- MESO $22.00
- ESRT $11.62
- Technical
- Relative Strength Index (RSI)
- MESO 60.94
- ESRT 33.01
- Support Level
- MESO $14.45
- ESRT $7.28
- Resistance Level
- MESO $16.23
- ESRT $7.52
- Average True Range (ATR)
- MESO 0.57
- ESRT 0.23
- MACD
- MESO 0.10
- ESRT -0.06
- Stochastic Oscillator
- MESO 63.12
- ESRT 3.90
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.